Blood cytokine, chemokine and gene expression in cholestasis patients with intractable pruritus treated with a molecular adsorbent recirculating system: A case series

Canadian Journal of Gastroenterology

Volumn 26, Issue 11, 2012, Pages 799-805

  Lisboa, Luiz F ^a   Asthana, Sonal ^a   Kremer, Andreas E ^b   Swain, Mark ^c   Bagshaw, Sean M ^a   Gibney, Noel ^a   Karvellas, Constantine J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cholestasis; Cytokine; Gene expression; Intractable pruritus; MARS

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; AUTOTAXIN; BILE ACID; BILIRUBIN; BILIRUBIN GLUCURONIDE; CHEMOKINE; COLESTYRAMINE; CREATININE; EARLY GROWTH RESPONSE FACTOR 3; EPHRIN A2; EPHRIN RECEPTOR B1; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; NALTREXONE; RANTES; RIFAMPICIN; SERUM AMYLOID A; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ALBUMIN DIALYSIS; ARTICLE; CASE REPORT; CHOLESTASIS; CHRONIC LIVER DISEASE; CLINICAL EFFECTIVENESS; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG TREATMENT FAILURE; END STAGE LIVER DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRACTABLE PRURITUS; INTRAHEPATIC CHOLESTASIS; PARTIAL THROMBOPLASTIN TIME; PATIENT SAFETY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; QUALITY OF LIFE; THROMBOCYTE COUNT;

EID: 84868530279     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/623862     Document Type: Article

References (58)

1. Battezzati PM, Podda M, Bianchi FB, et al. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group For The Study Of UDCA in PBC. J Hepatol 1993;17:332-8. (Pubitemid 23134930)
2. Matsuzaki Y, Tanaka N, Osuga T, et al. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastrenterol 1990;85:15-23. (Pubitemid 20038972)
3. Pares A, Caballeria L, Rodes J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial. UDCA-Cooperative Group From The Spanish Association For The Study Of The Liver. J Hepatol 2000;32:561-6. (Pubitemid 30180374)
4. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324:1548-54.
5. Hadzigiannis S, Hadzigiannis E, Makris A. A randomized controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis. Hepatology 1989;10:580 (Abst).
6. Vuoristo M, Farkkila M, Karvonen AL, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 1995;108:1470-8.
7. Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989;1:574-6. (Pubitemid 19074002)
8. Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966;50:323-32.
9. Kuiper EM, Van Erpecum KJ, Beuers U, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: Results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:1334-40.
10. Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995;123:161-7.
11. Bergasa NV, Schmitt JM, Talbot TL, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998;27:679-84. (Pubitemid 28103542)
12. Bergasa NV, Talbot TL, Alling DW, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992;102:544-9.
13. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. Gastroenterology 1997;113:1264-9. (Pubitemid 27418980)
14. Kremer AE, Martens JJ, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010;139:1008-18.
15. Alallam A, Barth D, Heathcote E J. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: Case reports. Can J Gastroenterol 2008;22:505-7. (Pubitemid 351943680)
16. Huster D, Schubert C, Achenbach H, Caca K, Mossner J, Berr F. Successful clinical application of extracorporal albumin dialysis in a patient with benign recurrent intrahepatic cholestasis (BRIC). Z Gastroenterol 2001;39(Suppl 2):13-4.
17. Quintero E, Puig L, PaRes A, Mazzara R, Castillo R, Rodes J. Utilidad del recambio plasmatico intermitente en la cirrosis biliar primaria. Gastroenterol Hepatol 1986;9:329-33.
18. Nakamura K, Ohkawa R, Okubo S, et al. Measurement of lysophospholipase D/autotaxin activity in human serum samples. Clin Biochem 2007;40:274-7. (Pubitemid 46108705)
19. Metz M, Stander S. Chronic pruritus - pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 2010;24:1249-60.
20. Breuer-Mcham J N, Marshall G D, Lewis D E, Duvic M. Distinct serum cytokines in AIDS-related skin diseases. Viral Immunol 1998;11:215-20. (Pubitemid 29178836)
21. Kimmel M, Alscher D M, Dunst R, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 2006;21:749-55. (Pubitemid 43378900)
22. Safford M, Collins S, Lutz MA, et al. Egr-2 And Egr-3 are negative regulators of T cell activation. Nat Immunol 2005;6:472-80. (Pubitemid 41716760)
23. Gomez-Martin D, Diaz-Zamudio M, Galindo-Campos M, Alcocer-Varela J. Early growth response transcription factors and the modulation of immune response: Implications towards autoimmunity. Autoimmun Rev 2010;9:454-8.
24. Collins S, Lutz MA, Zarek PE, Anders RA, Kersh GJ, Powell JD. Opposing regulation of T cell function by Egr-1/Nab2 And Egr-2/Egr-3. Eur J Immunol 2008;38:528-36.
25. De Santo C, Arscott R, Booth S, et al. Invariant NKT cells modulate the suppressive activity of Il-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol 2010;11:1039-46.
26. Wu J, Luo H. Recent Advances on T-cell regulation by receptor tyrosine kinases. Curr Opin Hematol 2005;12:292-7. (Pubitemid 41058393)
27. Holen HL, Shadidi M, Narvhus K, Kjosnes O, Tierens A, Aasheim HC. Signaling through ephrin-A ligand leads to activation of Src-family kinases, Akt phosphorylation, and inhibition of antigen receptor-induced apoptosis. J Leukoc Biol 2008;84:1183-91.
28. Carpenter S, Carlson T, Dellacasagrande J, et al. TRIL, a functional component of the TLR4 signaling complex, highly expressed in brain. J Immunol 2009;183:3989-95.
29. Kitamura T, Kabuyama Y, Kamataki A, et al. Enhancement of lymphocyte migration and cytokine production by EphrinB1 system in rheumatoid arthritis. Am J Physiol Cell Physiol 2008;294:C189-96.
30. Leckie P, Tritto G, Mookerjee R, Davies N, Jones D, Jalan R. 'Out-patient' albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther 2012;35:696-704.
31. Pares A, Herrera M, Aviles J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: Combined analysis of patients from three centers. J Hepatol 2010;53:307-12.
32. Lemoine M, Revaux A, Francoz C, et al. Albumin liver dialysis as pregnancy-saving procedure in cholestatic liver disease and intractable pruritus. World J Gastroenterol 2008;14:6572-4.
33. Silvagni E, Coli L, Stagni B, Stefoni S, Bolondi L. A case of intractable pruritus in Turner's syndrome successfully treated with molecular adsorbent recirculating system. Intern Emerg Med 2008;3:65-7.
34. Novelli G, Rossi M, Poli L, et al. Intractable pruritus in patients with hepatitis C virus. Transplant Proc 2006;38:1089-91. (Pubitemid 43815910)
35. Montero JL, Pozo JC, Barrera P, e al. Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). Transplant Proc 2006;38:2511-3.
36. Saich R, Collins P, Ala A, Standish R, Hodgson H. Benign recurrent intrahepatic cholestasis with secondary renal impairment treated with extracorporeal albumin dialysis. Eur J Gastroenterol Hepatol 2005;17:585-8. (Pubitemid 40592719)
37. Acevedo Ribo M, Moreno Planas J M, Sanz Moreno C, et al. Therapy of intractable pruritus with MARS. Transplant Proc 2005;37:1480-1. (Pubitemid 40712090)
38. Bellmann R, Feistritzer C, Zoller H, et al. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: A report of two cases. Asaio J 2004;50:387-91. (Pubitemid 38917890)
39. Pares A, Cisneros L, Salmeron JM, et al. Extracorporeal albumin dialysis: A procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004;99:1105-10. (Pubitemid 38917816)
40. Bellmann R, GraziaDei I W, Feistritzer C, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 2004;10:107-14.
41. Macia M, Aviles J, Navarro J, Morales S, Garcia J. Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis. Am J Med 2003;114:62-4. (Pubitemid 36126518)
42. Doria C, Mandala L, Smith J, et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl 2003;9:437-43. (Pubitemid 36443060)
43. Sturm E, Franssen CF, Gouw A, et al. Extracorporal albumin dialysis (MARS) improves cholestasis and normalizes low Apo A-I levels in a patient with benign recurrent intrahepatic cholestasis (BRIC). Liver 2002;22(Suppl 2):72-5.
44. Gay M, Pares A, Carrascal M, et al. Proteomic analysis of polypeptides captured from blood during extracorporeal albumin dialysis in patients with cholestasis and resistant pruritus. Plos One 2011;6:E21850.
45. Novelli G, Morabito V, Pugliese F, et al. Management of sepsis during MARS treatment in acute on chronic liver failure. Transplant Proc 2011;43:1085-90.
46. Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treAtment. Gut 2010;59:381-6.
47. Novelli G, Rossi M, Ferretti G, et al. Predictive criteria for the outcome of patients with acute liver failure treated with the albumin dialysis molecular adsorbent recirculating system. Ther Apher Dial 2009;13:404-12.
48. Novelli G, Annesini M C, Morabito V, et al. Cytokine level modifications: Molecular adsorbent recirculating system versus standard medical therapy. Transplant Proc 2009;41:1243-8.
49. Roth GA, Faybik P, Hetz H, et al. MCP-1 And MIP3-alpha serum levels in acute liver failure and molecular adsorbent recirculating system (MARS) treatment: A pilot study. Scand J Gastroenterol 2009;44:745-51.
50. Ilonen I, Koivusalo AM, Hockerstedt K, Isoniemi H. Albumin dialysis has no clear effect on cytokine levels in patients with life-threatening liver insufficiency. Transplant Proc 2006;38:3540-3. (Pubitemid 44908445)
51. Stadlbauer V, Krisper P, Aigner R, et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 2006;10:R169.
52. Isoniemi H, Koivusalo A M, Repo H, Ilonen I, Hockerstedt K. The effect of albumin dialysis on cytokine levels in acute liver failure and need for liver transplantation. Transplant Proc 2005;37:1088-90. (Pubitemid 40590799)
53. Di Campli C, Zocco MA, Gaspari R, et al. The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. Transplant Proc 2005;37:2551-3. (Pubitemid 41354666)
54. Auth MK, Kim HS, Beste M, et al. Removal of metabolites, cytokines and hepatic growth factors by extracorporeal liver support in children. J Pediatr Gastroenterol Nutr 2005;40:54-9. (Pubitemid 40180058)
55. Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized controlled study. Liver Transpl 2004;10:1109-19. (Pubitemid 39248408)
56. Luo HT, Wu M, Wang MM. Case report of the first severe acute respiratory syndrome patient in China: Successful application of extracorporeal liver support MARS therapy in multiorgan failure possibly induced by severe acute respiratory syndrome. Artif Organs 2003;27:847-9. (Pubitemid 37108626)
57. Ambrosino G, Naso A, Feltracco P, et al. Cytokines and liver failure: Modification of Tnf- And Il-6 in patients with acute on chronic liver decompensation treated with molecular adsorbent recycling system (MARS). Acta Biomed 2003;74(Suppl 2):7-9. (Pubitemid 38337521)
58. Guo LM, Liu JY, Xu DZ, et al. Application of molecular adsorbents recirculating system to remove no and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int 2003;23(Suppl 3):16-20.